Fragile X targeted pharmacotherapy: lessons learned and future directions

Our understanding of fragile X syndrome (FXS) pathophysiology continues to improve and numerous potential drug targets have been identified. Yet, current prescribing practices are only symptom-based in order to manage difficult behaviors, as no drug to date is approved for the treatment of FXS. Drug...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Neurodev Disord
Hlavní autoři: Erickson, Craig A., Davenport, Matthew H., Schaefer, Tori L., Wink, Logan K., Pedapati, Ernest V., Sweeney, John A., Fitzpatrick, Sarah E., Brown, W. Ted, Budimirovic, Dejan, Hagerman, Randi J., Hessl, David, Kaufmann, Walter E., Berry-Kravis, Elizabeth
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2017
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5467059/
https://ncbi.nlm.nih.gov/pubmed/28616096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s11689-017-9186-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky